Pre-made Milatuzumab benchmark antibody ( Whole mAb, anti-CD74 therapeutic antibody, Anti-CLIP/DHLAG/HLADG/II/Ia-GAMMA/p33 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Milatuzumab biosimilar, Whole mAb, Anti-CD74 Antibody: Anti-CLIP/DHLAG/HLADG/II/Ia-GAMMA/p33 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Milatuzumab (or hLL1) is an anti-CD74 humanized monoclonal antibody for the treatment of multiple myeloma non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-344-1mg	1mg	Inquiry
GMP-Bios-ab-344-10mg	10mg	Inquiry
GMP-Bios-ab-344-100mg	100mg	Inquiry
GMP-Bios-ab-344-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Milatuzumab biosimilar, Whole mAb, Anti-CD74 Antibody: Anti-CLIP/DHLAG/HLADG/II/Ia-GAMMA/p33 therapeutic antibody
INN Name	Milatuzumab
Target	CD74
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-I/II
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2007
Year Recommended	2008
Companies	Immunomedics
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Graft-versus-host disease;Haematological malignancies;Chronic lymphocytic leukaemia;Multiple myeloma;Non-Hodgkin's lymphoma;Systemic lupus erythematosus
Development Tech	na